Cilostazol
Who holds supplier records for Cilostazol? 7 organisations hold a current record for Cilostazol: an active US FDA Type II Drug Master File. A further 4 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (3), China (1), Italy (1), Netherlands (1) and 1 other country (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Cilostazol: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/cilostazol
Reading the evidence
- 7 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 5 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (7)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Cilostazol. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Chongqing Kangle Pharmaceutical Co., Ltd.ChinaActive DMF 22643, 22463, 25666 · latest filing Dec 2011
- Alembic Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 17475, 43201 · latest filing Feb 2026
- ALIVUS LIFE SCIENCES LTDIndia Company GMP cert on recordActive DMF 16876 · latest filing Oct 2003
- COHANCE LIFESCIENCES LTDIndia Company GMP cert on recordActive DMF 43181 · latest filing Dec 2025
- Dipharma Francis SrlItaly Company GMP cert on recordActive DMF 17050 · latest filing Dec 2003
- TAPI NL BVNetherlandsActive DMF 16722 · latest filing Jul 2003
- WAVELENGTH ENTERPRISES LTDIsrael Company GMP cert on recordActive DMF 16645 · latest filing Jun 2003
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (4)
Organisations whose Type II DMFs for Cilostazol are no longer active. These show a past filing, not current supply.
Show all 4 historical records
- India · Inactive DMF 21678 · filed Oct 2008
- RANBAXY LABORATORIES LTDInactive DMF 19076 · filed Dec 2005
- Belgium · Inactive DMF 17372 · filed May 2004
- Spain · Inactive DMF 17973 · filed Jan 2004
Overview
Cilostazol is a phosphodiesterase III inhibitor that suppresses platelet aggregation and is a direct arterial vasodilator used to improve symptoms of intermittent claudication in patients with peripheral vascular disease. It works by inhibiting platelet aggregation and expanding arteries to increase blood flow.
Chemical identity
- IUPAC name
- 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
- Canonical SMILES
- C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
- InChIKey
- RRGUKTPIGVIEKM-UHFFFAOYSA-N
- Synonyms
- Pletal API, nsc-758936, opc-13013, opc-21, pletal
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Phosphodiesterase 3 Inhibitor
- Mechanism of action
- Phosphodiesterase 3 Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Cilostazol?
7 organisations hold an active US FDA Type II Drug Master File or a CEP for Cilostazol: Chongqing Kangle Pharmaceutical Co., Ltd. (China), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), COHANCE LIFESCIENCES LTD (India), Dipharma Francis Srl (Italy), TAPI NL BV (Netherlands) and WAVELENGTH ENTERPRISES LTD (Israel). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Cilostazol Drug Master Files are active?
Chongqing Kangle Pharmaceutical Co., Ltd. (DMF 22643, 22463), Alembic Pharmaceuticals Limited (DMF 17475, 43201), ALIVUS LIFE SCIENCES LTD (DMF 16876), COHANCE LIFESCIENCES LTD (DMF 43181), Dipharma Francis Srl (DMF 17050), TAPI NL BV (DMF 16722) and WAVELENGTH ENTERPRISES LTD (DMF 16645). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Cilostazol records mean?
4 organisations have only inactive Type II DMFs for Cilostazol. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
How do I qualify a Cilostazol supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Cilostazol?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.